Skip to main content

Table 1 Demographics and baseline characteristics

From: Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials

 NMT
(n = 1943)
MT
(n = 3040)
Age, mean (SD), years61.3 (8.2)64.6 (7.8)
Sex, n (%)
 Male1193 (61.4)1893 (62.3)
Race, n (%)
 White1563 (80.4)2381 (78.3)
 Asian229 (11.8)482 (15.9)
 Black or African American139 (7.2)163 (5.4)
 Other12 (0.6)14 (0.4)
Smoking status
 Current, n (%)1244 (64.0)1284 (42.2)
 Former, n (%)699 (36.0)1756 (57.8)
 Number of packs/year smoked, mean (SD)49.5 (25.9)49.1 (26.2)
CAT score
 Total CAT score, mean (SD)17.8 (7.7)17.0 (7.4)
 Symptomatic (CAT ≥15), n (%)1257 (64.7)1825 (60.0)
mMRC grade, mean (SD)1.7 (1.0)1.8 (0.9)
COPD severity, n (%)
 Mild (GOLD 1)13 (0.7)17 (0.6)
 Moderate (GOLD 2)1230 (63.3)1534 (50.5)
 Severe (GOLD 3)644 (33.1)1327 (43.7)
 Very severe (GOLD 4)56 (2.9)162 (5.3)
GOLD 2017 category, n (%)
 A276 (14.2)453 (14.9)
 B1516 (78.0)2177 (71.6)
 C19 (1.0)54 (1.8)
 D125 (6.4)348 (11.4)
 Missing7 (0.4)8 (0.3)
COPD duration, mean (SD), years6.5 (6.3)7.6 (6.2)
  1. CAT COPD Assessment Test, COPD Chronic obstructive pulmonary disease, GOLD Global Initiative for Chronic Obstructive Lung Disease, mMRC Modified Medical Research Council scale, SD Standard deviation